The average one-year price target for Monte Rosa Therapeutics (NasdaqGS:GLUE) has been revised to $28.49 / share. This is an increase of 30.77% from the prior estimate of $21.78 dated December 18, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $17.17 to a high of $38.85 / share. The average price target represents an increase of 18.75% from the latest reported closing price of $23.99 / share.
What is the Fund Sentiment?
There are 287 funds or institutions reporting positions in Monte Rosa Therapeutics. This is an increase of 10 owner(s) or 3.61% in the last quarter. Average portfolio weight of all funds dedicated to GLUE is 0.12%, an increase of 24.11%. Total shares owned by institutions decreased in the last three months by 3.31% to 64,401K shares. 
The put/call ratio of GLUE is 0.95, indicating a bullish outlook.
What are Other Shareholders Doing?
NEA Management Company holds 7,692K shares representing 9.71% ownership of the company. No change in the last quarter.
Bvf holds 5,660K shares representing 7.15% ownership of the company. No change in the last quarter.
Versant Venture Management holds 5,653K shares representing 7.14% ownership of the company. No change in the last quarter.
Baker Bros. Advisors holds 4,916K shares representing 6.21% ownership of the company. No change in the last quarter.
Price T Rowe Associates holds 4,637K shares representing 5.86% ownership of the company. In its prior filing, the firm reported owning 6,326K shares , representing a decrease of 36.42%. The firm increased its portfolio allocation in GLUE by 13.75% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
